Vildagliptin/metformin fixed-dose combination

Abstract

Vildagliptin, a new oral antidiabetic agent, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The enzyme inactivates incretin hormones, i.e. peptides that play an important role in glucose homeostasis.

Keywords

• Vildagliptin
• metformin
• depeptidyl peptidase-4 inhibitor
• type 2 diabetes mellitus